World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0000015120
Reproduction Date:

Title: Interferon  
Author: World Heritage Encyclopedia
Language: English
Subject: Interferon alfa 2b, István Rosztóczy, Hepatitis B, Antiviral drug, History of biotechnology
Publisher: World Heritage Encyclopedia


=Journal+of+Proteome+Research&rft.pages=3527-36&rft.volume=9&rft_id=info%3Adoi%2F10.1021%2Fpr100326j&rft_id=info%3Apmid%2F20459142&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"> 
  • ^ a b c d Lin RJ, Liao CL, Lin E, Lin YL (September 2004). "Blocking of the Alpha Interferon-Induced Jak-Stat Signaling Pathway by Japanese Encephalitis Virus Infection". J. Virol. 78 (17): 9285–94.  
  • ^ a b Sen GC (2001). "Viruses and interferons". Annu. Rev. Microbiol. 55: 255–81.  
  • ^ a b Alcamí A, Symons JA,  
  • ^ Minks MA, West DK, Benvin S, Baglioni C (October 1979). "Structural requirements of double-stranded RNA for the activation of 2',5'-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells". J. Biol. Chem. 254 (20): 10180–3.  
  • ^ Miller JE, Samuel CE (September 1992). "Proteolytic cleavage of the reovirus sigma 3 protein results in enhanced double-stranded RNA-binding activity: identification of a repeated basic amino acid motif within the C-terminal binding region". J. Virol. 66 (9): 5347–56.  
  • ^ Chang HW, Watson JC, Jacobs BL (June 1992). "The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase". Proc. Natl. Acad. Sci. U.S.A. 89 (11): 4825–9.  
  • ^ Seo SH, Hoffmann E, Webster RG (August 2002). "Lethal H5N1 influenza viruses escape host anti-viral cytokine responses". Nature Medicine 8 (9): 950–954.  
  • ^ Paolicelli D, Direnzo V, Trojano M (14 September 2009). "Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis". Biologics: Targets & Therapy 3: 369–376.  
  • ^ a b Goldstein D, Laszlo J (Sep 1988). "The role of interferon in cancer therapy: a current perspective" (Free full text). CA: a cancer journal for clinicians 38 (5): 258–277.  
  • ^ Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, Kirkwood JM (Mar 2008). "Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion". Cancer 112 (5): 982–994.  
  • ^ Shepherd J, Waugh N, Hewitson P (2000). "Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review" (Free full text). Health technology assessment (Winchester, England) 4 (33): 1–67.  
  • ^ Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB (2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature 461 (7262): 399–401.  
  • ^ Ishikawa T (Oct 2008). "Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients" (Free full text). World Journal of Gastroenterology 14 (40): 6140–6144.  
  • ^ a b c Wilhelmus KR (2010). "Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis". Cochrane Database Syst Rev 12: CD002898.  
  • ^ Bhatti Z, Berenson CS (2007). "Adult systemic cat scratch disease associated with therapy for hepatitis C". BMC Infect Dis 7: 8.  
  • ^ Jamall IS, Yusuf S, Azhar M, Jamall S (November 2008). "Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?". World J. Gastroenterol. 14 (43): 6627–31.  
  • ^ "NIH Consensus Statement on Management of Hepatitis C: 2002". NIH Consens State Sci Statements 19 (3): 1–46. 2002.  
  • ^ Sharieff KA, Duncan D, Younossi Z (February 2002). "Advances in treatment of chronic hepatitis C: 'pegylated' interferons". Cleve Clin J Med 69 (2): 155–9.  
  • ^ Isaacs A, Lindenmann J (September 1957). "Virus interference. I. The interferon". Proc. R. Soc. Lond., B, Biol. Sci. 147 (927): 258–67.  
  • ^ Stewart II, WE, The Interferon System. Springer Veralg. Vienna 1979.
  • ^ Nagano Y, Kojima Y (October 1954). "Pouvoir immunisant du virus vaccinal inactivé par des rayons ultraviolets". C. R. Seances Soc. Biol. Fil. (in French) 148 (19–20): 1700–2.  
  • ^ Ho, M, and Enders, JF, An inhibitor of viral activity appearing in infected cell cultures. PNAS 45, 385-389, 1959
  • ^ Tan YH, Tischfield J, Ruddle FH (1973). "The linkage of genes for the human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G-21". J. Exp. Med. 137 (2): 317–30.  
  • ^ Tan YH (1976). "Chromosome 21 and the cell growth inhibitory effect of human interferon preparations". Nature 260 (5547): 141–3.  
  • ^ Meager A, Graves H, Burke DC, Swallow DM (1979). "Involvement of a gene on chromosome 9 in human fibroblast interferon production". Nature 280 (5722): 493–5.  
  • ^ Berthold W, Tan C, Tan YH (1978). "Chemical modifications of tyrosyl residue(s) and action of human-fibroblast interferon". Eur. J. Biochem. 87 (2): 367–70.  
  • ^ Berthold W, Tan C, Tan YH (1978). "Purification and in vitro labeling of interferon from a human fibroblastoid cell line". J. Biol. Chem. 253 (14): 5206–12.  
  • ^ a b Tan YH, Barakat F, Berthold W, Smith-Johannsen H, Tan C (1979). "The isolation and amino acid/sugar composition of human fibroblastoid interferon". J. Biol. Chem. 254 (16): 8067–73.  
  • ^ Zoon KC, Smith ME, Bridgen PJ, Anfinsen CB, Hunkapiller MW, Hood LE (1980). "Amino terminal sequence of the major component of human lymphoblastoid interferon". Science 207 (4430): 527–8.  
  • ^ Okamura H, Berthold W, Hood L, Hunkapiller M, Inoue M, Smith-Johannsen H, Tan YH (1980). "Human fibroblastoid interferon: immunosorbent column chromatography and N-terminal amino acid sequence". Biochemistry 19 (16): 3831–5.  
  • ^ Knight E, Hunkapiller MW, Korant BD, Hardy RW, Hood LE (1980). "Human fibroblast interferon: amino acid analysis and amino terminal amino acid sequence". Science 207 (4430): 525–6.  
  • ^ Pestka S (July 2007). "The interferons: 50 years after their discovery, there is much more to learn". J. Biol. Chem. 282 (28): 20047–51.  
  • ^ Weissenbach J, Chernajovsky Y, Zeevi M, Shulman L, Soreq H, Nir U, Wallach D, Perricaudet M, Tiollais P, Revel M (December 1980). "Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies". Proc. Natl. Acad. Sci. U.S.A. 77 (12): 7152–6.  
  • ^ Taniguchi T, Fujii-Kuriyama Y, Muramatsu M (July 1980). "Molecular cloning of human interferon cDNA". Proc. Natl. Acad. Sci. U.S.A. 77 (7): 4003–6.  
  • ^ Nagata S, Mantei N, Weissmann C (October 1980). "The structure of one of the eight or more distinct chromosomal genes for human interferon-alpha". Nature 287 (5781): 401–8.  
  • ^ Gray PW, Goeddel DV (August 1982). "Structure of the human immune interferon gene". Nature 298 (5877): 859–63.  
  • ^ Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsödi J, Boll W, Cantell K, Weissmann C (March 1980). "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity". Nature 284 (5754): 316–20.  
  • ^ US patent 6207146, Tan YH, Hong WJ, "Gene expression in mammalian cells.", issued 2001 
  • ^ Cantell K (1998). The story of interferon: the ups and downs in the life of a scientis. Singapore ; New York: World Scientific.  
  • ^ Tan YH, Armstrong JA, Ke YH, Ho M (1970). "Regulation of cellular interferon production: enhancement by antimetabolites". Proc. Natl. Acad. Sci. U.S.A. 67 (1): 464–71.  
  • ^ US patent 3773924, Ho M, Armstrong JA, Ke YH, Tan YH, "Interferon Production", issued 1973 
  • This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
    Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
    By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

    Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
    a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.